Funding for this research was provided by:
National Cancer Institute (T32CA225617, R01CA214491)
Received: 12 February 2021
Accepted: 22 July 2021
First Online: 11 August 2021
: This study was part of an ongoing longitudinal study and approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai Hospital (STUDY-17-00563). An alteration of HIPAA permission was granted to assess potential patient enrollment. Upon enrollment into the study, patients were walked through the full consenting process with a trained research assistant. The form includes a HIPAA section that asks for patient consent to the study team to review their medical record for research purposes. Consent was documented in writing. The IRB approved administration of this cross-sectional bone health study without a re-consent since surveys were administered to actively enrolled participants. We incorporated an introductory/screening script at the beginning of the survey where patients were informed of the optional bone health study. All participants provided verbal informed consent for the bone health study.
: Not applicable.
: The authors declare that they have no competing interests.